

Cost-effectiveness of cognitive behaviour therapy of cognitive behaviour therapy for recent onset schizophrenia patients with persistent and recurrent psychosis.

Submission date 20/12/2005	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
Registration date 20/12/2005	Overall study status Completed	<input type="checkbox"/> Protocol
Last Edited 07/01/2021	Condition category Mental and Behavioural Disorders	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr M van der Gaag

Contact details
Parnassia & Groningen University
Oude Haagweg 353
Den Haag
Netherlands
2552 ES
+31 (0)70 3917622
mark@van-der-gaag.nl

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

ZonMW 945-04-406

Study information

Scientific Title

Cost-effectiveness of cognitive behaviour therapy of cognitive behaviour therapy for recent onset schizophrenia patients with persistent and recurrent psychosis.

Acronym

COCOS

Study objectives

To determine the cost-effectiveness of CBT compared to care as usual in patients with a recent onset of schizophrenia, who suffer from persistent and recurrent symptoms of psychosis.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomised controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Not specified

Study type(s)

Not Specified

Participant information sheet

Health condition(s) or problem(s) studied

Schizophrenia

Interventions

Please note that, as of 30/07/2008, the end date of this trial has been updated from 01/12/2007 to 01/04/2008.

Interventions:

1. CBT by a cognitive therapist and a nurse therapist
2. CAU

Intervention Type

Other

Phase

Not Specified

Primary outcome measure

Days functioning in normal range based on PSYRAYS and SFS: minimal suffering and functional restrictions by delusions and/or hallucinations and SFS normal social functioning.

Secondary outcome measures

1. Medication compliance
2. Number of relapses
3. Psychiatric symptoms
4. Quality of life

Overall study start date

01/12/2004

Completion date

01/04/2008

Eligibility**Key inclusion criteria**

1. Schizophrenia patients in the first five years after onset
2. Age 18-64
3. Treatment resistant or recurrent psychosis

Participant type(s)

Patient

Age group

Adult

Lower age limit

18 Years

Upper age limit

64 Years

Sex

Both

Target number of participants

230

Key exclusion criteria

1. IQ<80
2. Severe addiction

- 3. No competence of Dutch language
- 4. 4 or more CBT sessions in the last year

Date of first enrolment

01/12/2004

Date of final enrolment

01/04/2008

Locations

Countries of recruitment

Netherlands

Study participating centre

Parnassia & Groningen University

Den Haag

Netherlands

2552 ES

Sponsor information

Organisation

University Medical Center Groningen (Netherlands)

Sponsor details

Hanzeplein 1

Groningen

Netherlands

9713 GZ

Sponsor type

Hospital/treatment centre

ROR

<https://ror.org/03cv38k47>

Funder(s)

Funder type

Research organisation

Funder Name

ZonMw

Alternative Name(s)

Netherlands Organisation for Health Research and Development

Funding Body Type

Private sector organisation

Funding Body Subtype

Other non-profit organizations

Location

Netherlands

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date**Individual participant data (IPD) sharing plan****IPD sharing plan summary**

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/01/2011	07/01/2021	Yes	No